Beam Therapeutics公布BEAM-302治疗α-1抗胰蛋白酶缺乏症1/2期试验最新积极数据 支持推进关键性开发阶段

美股速递
Yesterday

Beam Therapeutics近日公布了其在研疗法BEAM-302针对α-1抗胰蛋白酶缺乏症(AATD)的1/2期临床试验最新数据。这些积极结果有力支持该疗法向关键性临床开发阶段推进。试验数据显示,BEAM-302在安全性和有效性方面均表现出令人鼓舞的潜力,为后续研发奠定了坚实基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10